Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 16/20 | 0.58 |
| ▸ | PDE6C | P51160 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PDE1A | P54750 | 1/20 | 0.38 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.38 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5085819 | 0.95 | PDE5A (0.65) | PDE5APDE6CALDH1A1MAPTHSD17B10 | |
| SCHEMBL7167750 | 0.91 | PDE5A (0.54) | PDE5APDE6CALDH1A1MAPTHSD17B10 | |
| SCHEMBL6058528 | 0.87 | PDE5A (0.67) | PDE5APDE6CALDH1A1MAPTHSD17B10 | |
| SCHEMBL5990273 | 0.80 | PDE5A (0.50) | PDE5APDE6CALDH1A1MAPTHSD17B10 | |
| SCHEMBL29611957 | 0.79 | PDE5A (0.90) | PDE5APDE6C | |
| SCHEMBL146830 | 0.79 | PDE5A (0.90) | PDE5APDE6C | |
| SCHEMBL2437931 | 0.78 | PDE4A (0.53) | PDE5APDE6CALDH1A1MEN1KMT2A | |
| SCHEMBL5964550 | 0.77 | PDE5A (0.70) | PDE5APDE6C | |
| SCHEMBL7019550 | 0.77 | PDE5A (0.46) | PDE5APDE6CHSD17B10KMT2APDE1A | |
| SCHEMBL7446947 | 0.76 | ALDH1A1 (0.46) | PDE5APDE6CALDH1A1MAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1418896-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | Vivus, Inc. (US) | 2004-05-19 | — | — | EP | claimed |
| JP-2003525845-A | — | — | 2003-09-02 | — | — | JP | claimed |
| WO-2003000343-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | VIVUS, INC. (US) | 2003-01-03 | — | — | WO | claimed |
| EP-1027054-A4 | LOCAL ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | VIVUS INC (US) | 2002-11-04 | — | — | EP | claimed |
| EP-1237577-A2 | TRANSMUCOSAL COMPOSITION CONTAINING A PHOSPHODIESTERASE INHIBITOR FOR THE TREATMENT OF ERECTILE DYSFUNCTION | Vivus, Inc. (US) | 2002-09-11 | — | — | EP | claimed |
| WO-2001041807-A2 | TRANSMUCOSAL COMPOSITION CONTAINING A PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | VIVUS, INC. (US) | 2001-06-14 | — | — | WO | claimed |
| EP-1027054-A1 | LOCAL ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | Vivus, Inc. (US) | 2000-08-16 | — | — | EP | claimed |
| WO-1999021558-A2 | LOCAL ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | VIVUS, INC. (US) | 1999-05-06 | — | — | WO | claimed |
| EP-2512479-A1 | METHODS AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE | Exodos Life Sciences Limited Partnership (US) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011075655-A1 | METHODS AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE | EXODOS LIFE SCIENCES LIMITED PARTNERSHIP (US) | 2011-06-23 | — | — | WO | disclosed |
| US-20110107442-A1 | Treatment of Male Sexual Dysfunction | IXCHELSIS LIMITED (GB) | 2011-05-05 | — | — | US | disclosed |
| EP-2222665-A1 | AZETIDINES AS EP2 ANTAGONISTS | Pfizer Limited (GB) | 2010-09-01 | — | — | EP | disclosed |
| EP-2155666-A1 | AZETIDINE DERIVATIVES AND THEIR USE AS PROSTAGLANDIN E2 ANTAGONISTS | Pfizer Limited (GB) | 2010-02-24 | — | — | EP | disclosed |
| US-7649003-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC. (US) | 2010-01-19 | — | — | US | disclosed |
| WO-2002013798-A2 | TREATMENT OF THE INSULIN RESISTANCE SYNDROME WITH SELECTIVE CGMP PDE5 INHIBITORS | PFIZER LIMITED (GB) | 2002-02-21 | — | — | WO | disclosed |
| WO-2002003995-A2 | TREATMENT OF MALE SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 2002-01-17 | — | — | WO | disclosed |
| WO-2002002513-A1 | CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE | PFIZER LIMITED (GB) | 2002-01-10 | — | — | WO | disclosed |
| EP-1125582-A2 | Use of estrogen agonists / antagonists for the treatment of sexual dysfunction | Pfizer Products Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
| EP-1027054-A1 | LOCAL ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | Vivus, Inc. (US) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999021558-A2 | LOCAL ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | VIVUS, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110107442-A1 | Treatment of Male Sexual Dysfunction | OXTR, AVPR1B, AVPR2 | PDE5A 73/4885PDE6C 961/4885ALDH1A1 3966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.